Apellis Pharmaceuticals Inc (OQ:APLS)

Mar 19, 2024 03:00 pm ET
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of Cummins Inc. (NYSE: CMI), Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), Inspire Medical...
Mar 11, 2024 07:00 am ET
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadership in retina,...
Mar 06, 2024 04:05 pm ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan...
Mar 05, 2024 02:07 pm ET
Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of Driven Brands Holdings Inc. (NASDAQ: DRVN), Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), Inspire...
Feb 27, 2024 07:05 am ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2023 financial results and business highlights. “I am extremely proud of our team, their accomplishments and resilience in a year faced with many highs...
Feb 26, 2024 07:00 am ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences: TD Cowen 44th Annual Healthcare Conference: Fireside chat on Monday, March 4, 2024, at 2:10 p.m....
Feb 20, 2024 07:00 am ET
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, at 8:30 a.m. ET. To access the...
Feb 06, 2024 04:05 pm ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 4 new employees with a grant date of February 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive...
Jan 26, 2024 07:06 am ET
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of...
Jan 16, 2024 01:47 pm ET
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors. If you have continuously owned Apellis Pharmaceuticals...
Jan 08, 2024 09:00 am ET
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE® (pegcetacoplan injection) for...
Jan 05, 2024 04:05 pm ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 2 new employees with a grant date of January 2, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive...
Jan 02, 2024 07:00 am ET
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT. The event will be available via a live webcast from the...
Dec 28, 2023 07:00 am ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET. The event will be available via a...
Dec 14, 2023 12:09 pm ET
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors. If you have continuously owned Apellis Pharmaceuticals...
Dec 14, 2023 08:31 am ET
Thinking about trading options or stock in Apellis Pharmaceuticals, Meta Platforms, NVIDIA, Micron Technology, or Gold Fields Limited?
NEW YORK, Dec. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLS, META, NVDA, MU, and GFI.
Dec 14, 2023 07:00 am ET
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related...
Dec 11, 2023 07:00 am ET
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI® (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) for up to three years. The...
Dec 06, 2023 04:05 pm ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive...
Dec 06, 2023 12:49 pm ET
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors. If you have continuously owned Apellis Pharmaceuticals shares...
Nov 21, 2023 07:00 am ET
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:00 a.m. ET. The event will be available via a live...
Nov 06, 2023 04:05 pm ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a grant date of November 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive...
Nov 04, 2023 01:37 pm ET
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first-ever FDA-approved treatment for geographic atrophy (GA)...
Nov 02, 2023 09:00 pm ET
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of long-term stockholders following a class action complaint that was...
Nov 01, 2023 07:05 am ET
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced its third quarter 2023 financial results and business highlights. “We are thrilled with the progress we have made these past few months, despite the challenges we have faced, and look...
Oct 30, 2023 12:03 pm ET
Investigation Alert Apellis Pharmaceuticals, KeyCorp, RTX Corporation, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors. If you have continuously owned Apellis Pharmaceuticals...
Oct 25, 2023 07:00 am ET
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 8:00 a.m. ET. To access the live call by...
Oct 20, 2023 08:00 am ET
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to...
Oct 17, 2023 07:00 am ET
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranoproliferative...
Oct 06, 2023 09:31 am ET
Thinking about trading options or stock in NVIDIA, Tellurian, Albemarle Corporation, Apellis Pharmaceuticals, or Clearway Energy?
NEW YORK, Oct. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, TELL, ALB, APLS, and CWEN.
Oct 05, 2023 04:05 pm ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to seven new employees with a grant date of October 2, 2023, as equity...
Oct 05, 2023 07:00 am ET
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today provided an update on the launch of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “In only seven months, more than 100,000...
Oct 02, 2023 12:27 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Oct 02, 2023 11:16 am ET
DEADLINE ALERT for EOSE, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 02, 2023 07:00 am ET
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI® Injector. The EMPAVELI Injector is a compact, single-use, on-body device designed to enhance...
Oct 02, 2023 05:45 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
NEW YORK, Oct. 2, 2023 /PRNewswire/ -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders:
Oct 01, 2023 11:45 pm ET
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 30, 2023 07:00 pm ET
Lifshitz Law PLLC Announces Investigations of Apellis Pharmaceutics, Inc. (NASDAQ: APLS), RTX Corp. (NYSE: RTX), Live Nation Entertainment, Inc. (NYSE: LYV), and KeyCorp (NYSE: KEY)
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or...
Sep 30, 2023 04:46 pm ET
APLS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Cl
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Sep 29, 2023 10:50 pm ET
APELLIS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Apellis Phar
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company’s shares between January 28, 2021 and July 28, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.
Sep 29, 2023 09:00 pm ET
APELLIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS) in the United States District Court for the District of Delaware on behalf of all persons and entities who purchased or otherwise acquired Apellis securities between January 28, 2021 and January 28, 2023, both dates inclusive (the “Class Period”). Investors have until October 2, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 29, 2023 04:28 pm ET
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES, Sept. 29, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS).
Sep 29, 2023 04:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Sep 29, 2023 01:39 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
The Law Offices of Frank R. Cruz reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ:
Sep 29, 2023 12:41 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis...
Sep 28, 2023 01:00 pm ET
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES, Sept. 28, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS).
Sep 28, 2023 12:38 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 28, 2021 and July 28, 2023....
Sep 28, 2023 05:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Sept. 28, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit.
Sep 28, 2023 12:05 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company’s shares between January 28, 2021 and July 28, 2023, inclusive (the “Class...
Sep 27, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTX Corporation (NYSE: RTX), Eos Energy Enterprises (NASDAQ: EOSE), and Apellis...
Sep 27, 2023 12:43 pm ET
DEADLINE ALERT for PRTYQ, HAYW, APLS, LYV: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 27, 2023 12:40 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 27, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)
NEW YORK, Sept. 27, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc..
Sep 26, 2023 10:27 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - AP
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they...
Sep 26, 2023 11:15 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 26, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc..
Sep 25, 2023 05:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Sep 25, 2023 12:30 pm ET
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apell
Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)?Did you purchase your shares between January 28, 2021 and July 28, 2023, inclusive?Did you lose money in your investment in Apellis...
Sep 25, 2023 11:42 am ET
DEADLINE ALERT for EOSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 25, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc....
Sep 25, 2023 10:44 am ET
ROSEN, A LEADING AND RANKED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Sep 25, 2023 10:15 am ET
OCTOBER 2 DEADLINE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 25, 2023 07:30 am ET
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE® (pegcetacoplan injection), the first-ever treatment...
Sep 25, 2023 06:45 am ET
DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that the Apellis class action lawsuit, captioned Soderberg v. Apellis Pharmaceuticals, Inc., No. 23-cv-00834 (D. Del.), charges Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) along with...
Sep 24, 2023 03:20 pm ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 24, 2023 / TThe Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ: APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 22, 2023 10:50 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - AP
NEW ORLEANS, Sept. 22, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company's shares between January 28, 2021 and July 28, 2023, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of Delaware.
Sep 22, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Apellis, Party City, and Hayward and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), Party City Holdco, Inc. (OTC:...
Sep 22, 2023 03:44 pm ET
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Sept. 22, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS).
Sep 22, 2023 12:36 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Sep 21, 2023 02:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 21, 2023 02:15 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 21, 2023 12:58 pm ET
DEADLINE ALERT for PRTYQ, HAYW, APLS, LYV: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 21, 2023 12:35 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who...
Sep 21, 2023 05:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit.
Sep 20, 2023 08:57 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company’s shares between January 28, 2021 and July 28, 2023, inclusive (the “Class...
Sep 20, 2023 07:00 am ET
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apell
Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)?Did you purchase your shares between January 28, 2021 and July 28, 2023, inclusive?Did you lose money in your investment in Apellis...
Sep 19, 2023 10:35 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action La
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Sep 19, 2023 01:15 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Sep 19, 2023 12:59 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 28, 2021 and July 28, 2023....
Sep 19, 2023 12:49 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc....
Sep 19, 2023 12:16 pm ET
DEADLINE ALERT for EQSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 19, 2023 08:35 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 19, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)
NEW YORK, Sept. 19, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc..
Sep 18, 2023 12:30 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Sep 18, 2023 07:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 18, 2023 05:45 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
NEW YORK, Sept. 18, 2023 /PRNewswire/ -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders:
Sep 17, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTX Corporation (NYSE: RTX), Eos Energy Enterprises (NASDAQ: EOSE), and Apellis...
Sep 17, 2023 05:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Sep 17, 2023 07:20 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ: APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 15, 2023 10:50 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action La
NEW ORLEANS, Sept. 15, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company's shares between January 28, 2021 and July 28, 2023, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of Delaware.
Sep 15, 2023 01:07 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who...
Sep 15, 2023 11:00 am ET
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES, Sept. 15, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS).
Sep 14, 2023 05:07 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Sep 14, 2023 03:33 pm ET
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES, Sept. 14, 2023 /PRNewswire/ --  The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS).
Sep 14, 2023 12:46 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 28, 2021 and July 28, 2023....
Sep 14, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 14, 2023 05:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Sept. 14, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit.
Sep 13, 2023 10:20 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company’s shares between January 28, 2021 and July 28, 2023, inclusive (the “Class...
Sep 13, 2023 05:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
NEW YORK, Sept. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Sep 13, 2023 01:08 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Sep 13, 2023 09:30 am ET
DEADLINE ALERT for PRTYQ, HAYW, APLS, LYV: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 13, 2023 06:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 12, 2023 10:21 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - AP
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they...
Sep 12, 2023 12:05 pm ET
DEADLINE ALERT for EQSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 12, 2023 10:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc....
Sep 12, 2023 06:00 am ET
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 12, 2023 02:30 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Eos Energy Enterprises (NASDAQ: EOSE), Apellis Pharmaceuticals, Inc. (NASDAQ:...
Sep 12, 2023 12:45 am ET
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apell
Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)?Did you purchase your shares between January 28, 2021 and July 28, 2023, inclusive?Did you lose money in your investment in Apellis...
Sep 11, 2023 12:16 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who...
Sep 11, 2023 10:30 am ET
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Sep 11, 2023 05:45 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
NEW YORK, Sept. 11, 2023 /PRNewswire/ -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders:
Sep 11, 2023 04:30 am ET
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Sep 11, 2023 04:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 10, 2023 12:46 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Sep 08, 2023 05:34 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Sep 08, 2023 05:28 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Sep 08, 2023 12:36 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc.. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Sep 08, 2023 02:47 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 07, 2023 09:00 am ET
DEADLINE ALERT for PRTYQ, HAYW, APLS, LYV: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 07, 2023 03:30 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 06, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Eos Energy Enterprises (NASDAQ: EOSE), Apellis Pharmaceuticals, Inc. (NASDAQ:...
Sep 06, 2023 04:05 pm ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 5 new employees with a grant date of September 1, 2023, as equity...
Sep 06, 2023 03:21 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action La
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Sep 06, 2023 12:54 pm ET
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc.(APLS) Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging that the Company violated federal securities laws. Class Period: January 28, 2021 to July...
Sep 06, 2023 11:07 am ET
DEADLINE ALERT for EOSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 06, 2023 12:15 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 05, 2023 03:00 pm ET
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apell
Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)?Did you purchase your shares between January 28, 2021 and July 28, 2023, inclusive?Did you lose money in your investment in Apellis...
Sep 05, 2023 01:25 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc....
Sep 05, 2023 12:34 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who...
Sep 05, 2023 07:00 am ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences: Morgan Stanley 2023 Healthcare Conference:...
Sep 05, 2023 06:45 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 04, 2023 01:30 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LAS ANGELES, CA / ACCESSWIRE / September 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 02, 2023 07:00 pm ET
Lifshitz Law PLLC Announces Investigations of Apellis Pharmaceutics, Inc. (NASDAQ: APLS), RTX Corp. (NYSE: RTX), Live Nation Entertainment, Inc. (NYSE: LYV), and KeyCorp (NYSE: KEY)
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or...
Sep 01, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTX Corporation (NYSE: RTX), Eos Energy Enterprises (NASDAQ: EOSE), and Apellis...
Sep 01, 2023 01:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Sep 01, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 31, 2023 12:54 pm ET
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc. (APLS) Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging that the Company violated federal securities laws. Class Period: January 28, 2021 to July...
Aug 31, 2023 07:35 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 30, 2023 10:33 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company’s shares between January 28, 2021 and July 28, 2023, inclusive (the “Class...
Aug 30, 2023 10:30 pm ET
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action –
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important October 2, 2023 lead plaintiff deadline.
Aug 30, 2023 08:10 pm ET
APLS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that the Apellis class action lawsuit, captioned Soderberg v. Apellis Pharmaceuticals, Inc., No. 23-cv-00834 (D. Del.), charges Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and certain of its t
Aug 30, 2023 01:12 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc.. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Aug 30, 2023 12:06 pm ET
DEADLINE ALERT for EQSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 30, 2023 07:00 am ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences: Citi Annual BioPharma Conference: Fireside chat on...
Aug 30, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 29, 2023 09:20 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - AP
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they...
Aug 29, 2023 03:23 pm ET
Apellis Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; October 2, 2023 deadline
The Portnoy Law Firm advises Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) investors that a lawsuit filed on behalf of investors that purchased Apellis securities between February 23, 2022 to July 28, 2023, inclusive (the “Class Period”)...
Aug 29, 2023 08:30 am ET
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Against Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) and certain of its...
Aug 29, 2023 06:58 am ET
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the “Company”), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI®...
Aug 29, 2023 06:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 29, 2023 01:45 am ET
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ap
Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)? Did you purchase your shares between January 28, 2021 and July 28, 2023, inclusive? Did you lose money in your investment in Apellis...
Aug 28, 2023 01:14 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who...
Aug 28, 2023 10:06 am ET
DEADLINE ALERT for PRTYQ, HAYW, APLS, LYV: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 28, 2023 09:35 am ET
APLS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that the Apellis class action lawsuit, captioned Soderberg v. Apellis Pharmaceuticals, Inc., No. 23-cv-00834 (D. Del.), charges Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and certain of...
Aug 28, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 27, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Eos Energy Enterprises (NASDAQ: EOSE), Apellis Pharmaceuticals, Inc. (NASDAQ:...
Aug 26, 2023 01:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 26, 2023 10:44 am ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Aug 25, 2023 12:31 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc.. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Aug 25, 2023 06:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 24, 2023 02:30 pm ET
APLS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Apellis Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that the Apellis class action lawsuit, captioned Soderberg v. Apellis Pharmaceuticals, Inc., No. 23-cv-00834 (D. Del.), charges Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) as well as certain o
Aug 24, 2023 12:54 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who...
Aug 24, 2023 11:13 am ET
DEADLINE ALERT for EQSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 23, 2023 11:04 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc....
Aug 22, 2023 10:41 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action La
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Aug 22, 2023 04:43 pm ET
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare events of retinal vasculitis reported in real-world treatment with SYFOVRE® (pegcetacoplan...
Aug 22, 2023 12:39 pm ET
APLS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging that the Company violated federal securities laws. Class Period: January 28, 2021 to July...
Aug 22, 2023 09:01 am ET
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Against Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) and certain of its...
Aug 22, 2023 07:00 am ET
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apell
Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)?Did you purchase your shares between January 28, 2021 and July 28, 2023, inclusive?Did you lose money in your investment in Apellis...
Aug 22, 2023 05:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 21, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTX Corporation (NYSE: RTX), and Eos Energy Enterprises (NASDAQ: EOSE), and...
Aug 21, 2023 01:31 pm ET
APLS Stockholders Should Contact Robbins LLP for Information About the Class Action Involving Apellis Pharmaceuticals, Inc.
Robbins LLP reminds investors that a shareholder filed a class action against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of persons or entities who purchased or otherwise acquired shares of Apellis common stock between January 28, 2021...
Aug 21, 2023 01:22 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 – (NASDAQ: APLS)
The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc.. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Aug 21, 2023 10:00 am ET
APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / August 21, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ:APLS) between January 28, 2021 and July 28, 2023.
Aug 21, 2023 09:30 am ET
DEADLINE ALERT for PRTYQ, HAYW, APLS, LYV: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 21, 2023 06:00 am ET
INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ: APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 20, 2023 02:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 20, 2023 12:10 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Aug 20, 2023 06:30 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ: APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 19, 2023 07:15 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ: APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 18, 2023 02:15 pm ET
APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ:APLS) between January 28, 2021 and July 28, 2023.
Aug 18, 2023 12:36 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ:
Aug 18, 2023 12:30 pm ET
APLS LAWSUIT ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who...
Aug 18, 2023 11:30 am ET
APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ:APLS) between January 28, 2021 and July 28, 2023.
Aug 17, 2023 11:15 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 17, 2023 12:51 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
Law Offices of Howard G. Smith reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS) common stock between January 28, 2021 and July 28, 2023, inclusive (the “Class Period
Aug 17, 2023 11:30 am ET
APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / August 17, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ:APLS) between January 28, 2021 and July 28, 2023.
Aug 17, 2023 11:18 am ET
DEADLINE ALERT for EQSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 16, 2023 10:49 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company’s shares between January 28, 2021 and July 28, 2023, inclusive (the “Class...
Aug 16, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTX Corporation (NYSE: RTX), and Eos Energy Enterprises (NASDAQ: EOSE), and...
Aug 16, 2023 08:27 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”), of the important...
Aug 16, 2023 12:06 pm ET
APLS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging that the Company violated federal securities laws. Class Period: January 28, 2021 to July...
Aug 15, 2023 10:13 pm ET
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - AP
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they...
Aug 15, 2023 12:24 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 28, 2021 and July 28, 2023....
Aug 15, 2023 11:00 am ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Apellis Pharmaceuticals, Inc. (APLS) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ:
Aug 14, 2023 06:01 pm ET
APLS Stock News: Investors with Significant Losses in Apellis Pharmaceuticals, Inc. Should Contact Robbins LLP About Recovery
Robbins LLP reminds investors that a shareholder filed a class action against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of persons or entities who purchased or otherwise acquired shares of Apellis common stock between January 28, 2021...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.